切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2024, Vol. 17 ›› Issue (02) : 229 -233. doi: 10.3877/cma.j.issn.1674-6902.2024.02.011

论著

肺曲霉菌病患者的影像学及临床特征分析
游雅婷1, 刘熙1, 白莉1,†(), 郭亮1,†()   
  1. 1. 400037　重庆，陆军（第三）军医大学第二附属医院呼吸与危重症医学科
  • 收稿日期:2024-01-07 出版日期:2024-04-25
  • 通信作者: 白莉, 郭亮
  • 基金资助:
    重庆市自然科学基金(CSTB2023NSCQ-MSX0936)

Analysis of imaging and clinical features of patients with pulmonary aspergillosis

Yating You1, Xi Liu1, Li Bai1,†(), Liang Guo1,†()   

  1. 1. Institute of Respiratory Disease, The Second Affiliated Hospital (Xinqiao Hospital), Army Medical University, Chongqing, China
  • Received:2024-01-07 Published:2024-04-25
  • Corresponding author: Li Bai, Liang Guo
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

游雅婷, 刘熙, 白莉, 郭亮. 肺曲霉菌病患者的影像学及临床特征分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 229-233.

Yating You, Xi Liu, Li Bai, Liang Guo. Analysis of imaging and clinical features of patients with pulmonary aspergillosis[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(02): 229-233.

目的

分析有或无基础疾病患肺曲霉菌病(pulmonary aspergillosis)的流行病学，早期识别肺曲霉菌病患者的特征，以指导临床诊疗。

方法

回顾性分析2020年9月至2022年7月我院收治的肺曲霉菌病患者39例为对象，分无基础疾病为观察组17例和有基础疾病组为对照组22例，收集患者的性别、年龄、职业；症状，糖皮质激素使用史，抗生素使用史，胸部影像学特征及实验室检查，包括血常规、血沉、肝功能、肾功能、凝血功能、D-二聚体，比较两组数据。

结果

39例肺曲霉菌病患者中，年龄大于60岁观察组3例(17.65%)，对照组13例(59.09%)(P<0.05)；糖皮质激素使用史对照组7例(31.82%)，观察组17例中无使用者(P<0.05)；胸部影像不规则高密度影观察组7例(41.18%)，对照组17例(77.27%)(P<0.05)；肺部单侧病变观察组13例(76.47%)，对照组7例(31.82%)(P<0.05)；观察组尿素氮5.58[3.85～6.3]mmol/L，D-二聚体0.14[0.08～0.44]mg/L低于对照组6.67[5.09～10.53]mmol/L，0.73(0.26～1.17)mg/L(P<0.05);观察组血红蛋白130.00(124.00～134.00)g/L，总蛋白(69.60±7.41)g/L，白蛋白40.90(33.15～43.75)g/L高于对照组106.00(85.75～117.00)g/L，(58.90±9.45)g/L，31.70(27.93～38.93)g/L(P<0.05)。

结论

肺曲霉菌病可发生在肺部单侧，以肺结节、肺空洞及不规则高密度阴影表现；高龄、尿素氮、血红蛋白、总蛋白、白蛋白水平和D二聚体浓度是区别有无基础疾病患肺曲霉菌病的主要因素。

关键词: 肺曲霉菌病, 影像学, 临床特征
Objective

To analyze the epidemiological characteristics of pulmonary aspergillosis (PA) with or without underlying diseases, and to early identify the characteristics of pulmonary aspergillosis without underlying diseases to guide clinical diagnosis and treatment.

Method

A total of 39 patients with pulmonary aspergillosis admitted to our hospital from September 1, 2020 to July 1, 2022 were retrospectively analyzed. They were divided into the observation group 17 cases without underlying diseases and the control group 22 cases with underlying diseases. The gender, age, occupation, symptoms, history of glucocorticoid use, history of antibiotic use, chest imaging characteristics and laboratory examination of the patients were collected. Including blood routine, erythrocyte sedimentation rate, liver function, renal function, coagulation function, D-dimer, the two groups were statistically analyzed.

Result

Among the 39 patients with pulmonary aspergillosis, there were 3 cases (17.65%) in the observation group and 13 cases (59.09%) in the control group aged over 60 years (P<0.05). There were 7 cases (31.82%) of glucocorticoid use history in the control group, and no cases in the observation group, the difference between the two groups was statistically significant (P=0.012). There were 7 cases (41.18%) of irregular high density shadow in the observation group and 17 cases (77.27%) in the control group (P<0.05). There were 13 cases (76.47%) in the observation group and 7 cases (31.82%) in the control group with unilateral lung lesions (P<0.05). Blood urea nitrogen 5.58[3.85-6.3]mmol/L in the observation group, 6.67[5.09-10.53]mmol/L in the control group (P<0.05), D-dimer 0.14[0.08-0.44]mg/L in the observation group, 0.73(0.26-1.17)mg/L in the control group, the difference was statistically significant (P<0.05). The difference between the two groups was statistically significant (P<0.05). Hemoglobin was 130.00(124.00-134.00)g/L in the observation group and 106.00(85.75-117.00)g/L in the control group (P<0.05). Total protein was(69.60±7.41)g/L in the observation group and (58.90±9.45)g/Lin the control group (P<0.05). Albumin was 40.90(33.15-43.75)g/L in the observation group and 31.70(27.93-38.93)g/L in the control group (P<0.05).

Conclusions

Pulmonary aspergillosis can occur in one side of the lung, pulmonary nodules, pulmonary cavities and irregular high-density shadows. Advanced age, blood urea nitrogen, hemoglobin, total protein levels, albumin levels and D-dimer are the main factors to distinguish pulmonary aspergillosis with or without underlying diseases.

Key words: Pulmonary aspergillosis, Imaging, Clinical features
表1 两组肺曲霉菌病患者的基线特征及临床表现[n(%)]
临床资料 观察组(n＝17) 对照组(n＝22) P值
男性 9(52.94) 11(50.00) 1
年龄(>60岁) 3(17.65) 13(59.09) 0.020
咳嗽 15(88.24) 17(77.27) 0.438
发热 3(17.65) 8(36.36) 0.288
呼吸窘迫 3(17.65) 10(45.45) 0.093
咯血或痰血 7(41.18) 9(40.91) 1
胸痛 4(23.53) 3(13.64) 0.677
糖皮质激素使用史 0(0.00) 7(31.82) 0.012
抗生素使用史 8(47.06) 11(50.00) 1
图1 肺曲霉菌病典型胸部影像学表现。注：A：有基础疾病患者胸部CT；B：无基础疾病患者胸部CT
表2 两组肺曲霉菌病患者胸部影像学特征分析[n(%)]
影像表现 观察组(n＝17) 对照组(n＝22) P值
肺部单侧病变 13(76.47) 7(31.82) 0.010
肺结节 11(64.71) 11(50.00) 0.517
不规则高密度阴影 7(41.18) 17(77.27) 0.045
肺空洞 11(64.71) 8(36.36) 0.111
病变气道分布 5(29.41) 8(36.36) 0.740
表3 肺曲霉菌病患者的血常规、凝血功能及生化指标(中位数【第25百分位数-第75百分位数】)
变量指标 观察组(n＝17) 对照组(n＝22) P值
非正态分布数据      
WBC (109/L) 6.86(6.13～13.08) 7.13(5.29～14.07) 0.944
Neutrophils (109/L) 5.00(3.54～7.95) 5.56(3.84～11.71) 0.620
Hb(g/L) 130.00(124.00～134.00) 106.00(85.75～117.00) 0.007
PLT(109/L) 235.00(175.5～311.00) 163.50(44.00～322.25) 0.074
ESR(mm/1 h) 36.93(9.00～44.5) 57.50(10.58～74.25) 0.228
Proalbumin(g/L) 200.00(121.00～234.50) 109.00(48.50～224.25) 0.153
UREA(mmol/L) 5.58(3.85～6.30) 6.67(5.09～10.53) 0.046
CREA(μmol/L) 64.10(54.95～73.60) 73.65(51.70～103.90) 0.428
TBIL(μmol/L) 9.60(8.50～17.85) 13.30(9.90～17.90) 0.269
DBIL(μmol/L) 2.30(1.35～4.40) 2.75(1.73～5.18) 0.275
D-Dimmer(mg/L) 0.14(0.08～0.44) 0.73(0.26～1.17) 0.01
ALB(g/L) 40.90(33.15～43.75) 31.70(27.93～38.93) 0.023
正态分布数据      
FBG (g/L) 3.76±1.44 4.21±1.95 0.429
TP(g/L) 69.60±7.41 58.90±9.45 0
1
任之栋，张　巧，张玉江，等. 慢性阻塞性肺疾病合并慢性肺曲霉菌病的高危因素及临床特征分析[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(1): 11-16.
2
Bassetti M, Garnacho-Montero J, Calandra T, et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients[J]. Intensive Care Med，2017, 43: 1225-1238.
3
Paramythiotou E, Frantzeskaki F, Flevari A, et al. Invasive fungal infections in the ICU: how to approach, how to treat[J]. Molecules, 2014, 19: 1085-1119.
4
Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, et al. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients[J]. Intensive Care Med, 2007, 33: 1694-1703.
5
Denning DW. Global incidence and mortality of severe fungal disease[J]. Lancet Infect Dis, 2024: S1473-3099(24)00103-8.
6
Ao Z, Xu H, Li M, et al. Clinical characteristics, diagnosis, outcomes and lung microbiome analysis of invasive pulmonary aspergillosis in the community-acquired pneumonia patients[J]. BMJ Open Respir Res, 2023, 10(1): e001358.
7
Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery[J]. J Clin Oncol, 1997, 15(1): 139-147.
8
Salzer HJ, Cornely OA. Awareness of predictors of mortality may help improve outcome in chronic pulmonary aspergillosis[J]. Eur Respir J, 2017，49(2): 1602520.
9
Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis[J]. Clin Infect Dis, 2008, 47(9): 1176-1184.
10
Bulpa P, Duplaquet F, Dimopoulos G, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease exacerbations[J]. Semin Respir Crit Care Med, 2020, 41(6): 851-861.
11
Chotirmall SH, Martin-Gomez MT. Aspergillus species in bronchiectasis：Challenges in the cystic fibrosis and non-cystic fibrosis airways[J]. Mycopathologia, 2018, 183(1): 45-59.
12
Tudesq JJ, Peyrony O, Lemiale V, et al. Invasive pulmonary aspergillosis in nonimmunocompromised hosts[J]. Semin Respir Crit Care Med, 2019, 40(4): 540-547.
13
Bouza E, Guinea J, Pelaez T, et al. Workload due to aspergillus fumigatus and signifcance of the organism in the microbiology laboratory of a general hospital[J]. J Clin Microbiol, 2005, 43(5): 2075-2079.
14
Fontana L, Perlin DS, Zhao Y, et al. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients[J]. Clin Infect Dis, 2020 , 70(5): 723-730.
15
Godoy MCB, Ferreira Dalla Pria HR, Truong MT，et al. Invasive fungal pneumonia in immunocompromised patients[J]. Radiol Clin North Am, 2022, 60(3): 497-506.
16
Dandachi D, Wilson Dib R, Fernández-Cruz A, et al. Invasive pulmonary aspergillosis in patients with solid tumours: Risk factors and predictors of clinical outcomes[J]. Ann Med, 2018, 50(8): 713-720.
17
Lao M, Li C, Li J, et al. Opportunistic invasive fungal disease in patients with type 2 diabetes mellitus from Southern China: Clinical features and associated factors[J]. J Diabetes Investig, 2020, 11(3): 731-744.
18
Feng C, Zhang M, Zhang S, et al. Therapeutic effects of pentoxifylline on invasive pulmonary aspergillosis in immunosuppressed mice[J]. BMC Pulm Med, 2021, 21(1): 31.
19
Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study[J]. Lancet Respir Med, 2018, 6(10): 782-792.
20
Blot S, Rello J, Koulenti D. Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together[J]. Curr Opin Crit Care, 2019, 25(5): 430-437.
21
陈　虎，陈　亮，杨　健，等. 免疫正常宿主侵袭性气管支气管曲霉病一例[J]. 中国呼吸与危重监护杂志，2019, 18(6): 581-583.
22
Otu A, Kosmidis C, Mathioudakis AG, et al. The clinical spectrum of aspergillosis in chronic obstructive pulmonary disease[J]. Infection, 2023, 51(4): 813-829.
23
Zhong H, Wang Y, Gu Y, et al. Clinical features, diagnostic test performance, and prognosis in different subtypes of chronic pulmonary aspergillosis[J]. Front Med (Lausanne), 2022, 9: 811807.
24
Allwood BW, Byrne A, Meghji J, et al. Post-tuberculosis lung disease：Clinical review of an under-recognised global challenge[J]. Respiration, 2021, 100(8): 751-763.
25
Pakpoom P, Methee C. Chronic pulmonary aspergillosis following nontuberculous mycobacterial infections: An emerging disease[J]. J Fungi (Basel), 2020, 6(4): 346.
26
胡　群，卓惠长，徐礼裕，等. 吸入糖皮质激素致侵袭性肺曲霉病一例[J]. 中华结核和呼吸杂志，2016, 39(6): 480-481.
27
Raju S, Ghosh S, Mehta AC. Chest CT signs in pulmonary disease: A pictorial review[J]. Chest, 2017, 151(6): 1356-1374.
28
Caillot D, Mannone L, Cuisenier B, et al. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients[J]. Clin Microbiol Infect, 2001, 7(Suppl 2): 54-61.
29
Bulpa P, Bihin B, Dimopoulos G, et al. Which algorithm diagnoses invasive pulmonary aspergillosis best in ICU patients with COPD？[J]. Eur Respir J, 2017, 50(3): 1700532.
30
Guinea J, Torres-Narbona M, Gijon P, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome[J]. Clin Microbiol Infect, 2010, 16(7): 870-877.
[1] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[2] 王培蕾, 夏罕生, 俞清, 闻捷先, 黄备建. IgG4相关性乳腺炎多模态影像学表现及其治疗转归一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(04): 244-247.
[3] 王典, 刘双赫, 曾峥. 肩关节镜术后肌肉功能改变对颈椎形态及矢状面参数影响的自身前后对照队列研究[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 371-378.
[4] 丁科, 张亚琼, 刘杰, 邓莉平, 张永喜, 熊勇. 获得性免疫缺陷综合征相关淋巴瘤患者的临床特征及生存状况的变化趋势[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 278-284.
[5] 唐金侨, 叶宇佳, 王港, 赵彬, 马艳宁. 医学影像学检查方法在颞下颌关节紊乱病中临床应用研究进展[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 406-411.
[6] 张超, 张珍, 马梁, 穆欢欢, 刘彩玲. 腹腔镜胰十二指肠切除术术后C级胰瘘患者临床特征及影响因素研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 675-678.
[7] 王华, 曹素娥, 吴建杰, 狄金明. 膀胱炎性肌纤维母细胞瘤四例诊治报告并文献复习[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 547-552.
[8] 赖圣杰, 方欣, 方友强. 2023年欧洲内分泌学会及加拿大泌尿外科学会肾上腺偶发瘤诊疗指南解读[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 309-312.
[9] 杨柳, 陈佳, 孙雅娟, 陈娇, 谭明超, 龚明福. 抗中性粒细胞胞浆抗体相关性血管炎的胸部CT 及临床特征分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 744-749.
[10] 张燕, 杨跃青, 邱峥. IgG 联合血清细胞因子对肺结核并发慢性肺曲霉菌病的诊断意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 809-812.
[11] 杨攀, 黄晓寒, 邓才霞, 周利航, 周向东, 罗虎. SMARCA4缺失的胸部未分化肿瘤临床特征及预后分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 529-534.
[12] 王洪, 王骏华, 范建楠. 人工智能技术在肩袖损伤中的研究进展[J/OL]. 中华肩肘外科电子杂志, 2024, 12(04): 356-361.
[13] 潘冬生, 梁国标. 颅脑创伤治疗的最新进展与未来趋势[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(04): 193-197.
[14] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[15] 甘曦, 廖鑫. 胃癌旁肿瘤沉积与CT影像学特征、血清指标及病理特征的关联性分析[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 422-425.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？